Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 6th:Harrow, Inc. (HROW) : This eyecare pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 164.3% over the last 60 days.Harrow’s shares gained 108.4% over the last three months compared with the S&P 500’s advance of 11.1%. The company possesses a Momentum Score  of B.Orla Mining Ltd. (ORLA) : This mining company has a Zac ...

Investors might want to bet on Harrow (HROW) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a c ...

Shares of Harrow (HROW) have gained 5% over the past four weeks to close the last trading session at $47.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $59.45 indicates a potential upside of 26%.The mean estimate comprises four short-term price targets with a standard deviation of $12.23. While the lowest estimate of $44.80 indicates a 5.1% decline from the current price le ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

行业概况 - 医疗保健行业是美国最大的行业之一,预计到2024年将达到近4.9万亿美元 [1] - 该行业包括一些最大和最有利可图的公司 [1] 公司概况 - High Dividend Opportunities是一个拥有8000多名成员的收益投资者和退休人员社区 [1] - 该社区的收益方法能够产生强劲的回报,不受市场波动的影响,使退休投资更加简单轻松 [1] - 该社区提供一个目标收益率为9-10%的模型投资组合 [1]

Harrow (HROW) shares soared 8.4% in the last trading session to close at $49.75. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.8% gain over the past four weeks. Earlier this week, the company relaunched its ophthalmology drug, Triesence, which is approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. This might have driven the sha ...

Shares of Harrow Inc (HROW, Financial) surged 3.26% in mid-day trading on Oct 2. The stock reached an intraday high of $46.10, before settling at $45.90, up from its previous close of $44.45. This places HROW 3.47% below its 52-week high of $47.55 and 503.95% above its 52-week low of $7.60. Trading volume was 127,229 shares, 19.9% of the average daily volume of 640,221. Wall Street Analysts Forecast Based on the one-year price targets offered by 4 analysts, the average target price for Harrow Inc (HROW, Fin ...

财务数据和关键指标变化 - 公司实现了创纪录的季度收入48.9百万美元,同比增长46%,环比增长42% [15] - 公司预计下半年收入将超过上半年,特别是TRIESENCE产品重新上市后 [18] - 公司预计2024年全年收入将超过180百万美元,不包括TRIESENCE的贡献 [18] 各条业务线数据和关键指标变化 - 视网膜市场产品IHEEZO的季度销量增长约98% [19] - 干眼症产品VEVYE在第二季度的处方量增长212% [23] - 前段市场产品收入环比增长超过40% [69][72] 各个市场数据和关键指标变化 - IHEEZO已与24家战略性视网膜诊所签订供应协议,其中10家是在第二季度 [19] - VEVYE的商业保险覆盖率达到58%,Medicaid覆盖率达到80%,预计将在第三季度达到100% [25] 公司战略和发展方向及行业竞争 - 公司将继续投资扩大VEVYE销售团队,覆盖全国59个市场中的36个 [27] - 公司正在积极寻找新的收购机会,以扩大产品组合并提升公司在眼科领域的地位 [85][90] 管理层对经营环境和未来前景的评论 - 管理层对IHEEZO、VEVYE和TRIESENCE的未来前景表示乐观 [19-21][23-29][63-67] - 管理层认为公司有望成为北美领先的眼科制药公司 [30] 其他重要信息 - 公司将继续保持谨慎和纪律,不会过度扩张销售团队 [36-37][49-51][96-97] - 公司正在积极推进TRIESENCE的重新上市工作,预计将在今年第四季度实现 [21-22][63-67] 问答环节重要的提问和回答 问题1 **Jeffrey Cohen 提问** 关于VEVYE的Medicare覆盖情况 [33] **Mark Baum 回答** 公司正在积极推进VEVYE的Medicare覆盖,预计将在明年第一季度实现 [34][57] 问题2 **Chase Knickerbocker 提问** 关于IHEEZO供应协议的具体情况 [41] **Mark Baum 回答** 这些协议为公司提供了进入大型诊所集团的渠道,但需要分阶段实施 [42-45] 问题3 **Mayank Mamtani 提问** 关于IHEEZO和VEVYE的年度贡献情况 [78-80] **Mark Baum 和 Andrew Boll 回答** 公司不会披露具体的平均售价信息,但会随着市场准入的提升而不断改善 [79-82]

业绩展望 - 公司预计2027年年收入潜力超过5亿美元[4] - 核心毛利率将继续提升至80%左右，调整后的EBITDA有实质增长[5] 新产品和技术研发 - IHEEZO于2023年5月推出，2024年及以后持续增长[4] - VEVYE于2024年1月推出，具有领先市场潜力[4] - TRIESENCE计划在2024年重新推出，产品受到客户青睐[4] - MELT-300预计在2024年第四季度推出，具有潜在市场影响[53] 市场扩张和并购 - ImprimisRx稳定现金生产商，预计2024年收入增长超过10%[4] 用户数据 - Natacyn覆盖2.74亿人次，ILEVRO覆盖2.34亿人次[19] - VEVYE的处方量在2024年第一季度和第二季度有显著增长[29][34]

Harrow (HROW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 48%. A quarter ago, it was expected that this pharmaceutical and drug compounding company would post a loss of $0.25 per share when it actually produced a loss of $0.28, delivering a surprise of -12%. Over the last four quarters, ...